Skip to main content
NRIX logo

NRIX · Nurix Therapeutics, Inc.

Track NRIX — free
$26.96 +0.69 (+2.63%) At close · Aug 25
Market Cap
$2.75B
Shares
103.78M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-06-23 BTK A428D is a recurrent, pan-resistance mutation in patients with acquired resistance to BTK degraders Event
2026-06-08 Earnings conference call (announced in 8-K) Earnings call
2026-06-08 Unlocking the Full Potential of Bexobrutideg Event
2026-06-03 Jefferies Global Healthcare Conference Conference
2026-05-20 2026 RBC Capital Markets Global Healthcare Conference Conference
2026-05-15 2026 Annual Meeting of Stockholders Shareholder meeting
2026-05-14 BTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria Event
2026-04-21 Discovery and Characterization of CBL-B Intramolecular Glue Inhibitors That Increase T Cell Activation and Suppress Tumor Growth Event
2026-04-20 NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitor Event
2026-04-20 NRX-0305 is an Orally Bioavailable, Pan-Mutant BRAF Degrader that Exhibits Single Agent and Combination Efficacy with MEKi or anti-EGFR Across Class 1/2/3 BRAF Mutant Cancers Event
2026-04-20 NRX-0305: an Orally Bioavailable, CNS Penetrant, Pan-Mutant BRAF Degrader Demonstrates Robust Efficacy in Intracranial Models of Melanoma Brain Metastasis and Primary Glioma Event
2026-04-13 25th Annual Needham Virtual Healthcare Conference Conference
2026-03-24 Combinatorial Optimization of Degrader-Antibody Conjugates Enabled by Automation Event
2026-01-12 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-08 Webcast to Discuss Data Presented at 67th American Society of Hematology (ASH) Annual Meeting Shareholder meeting
2025-12-08 Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study Event
2025-12-06 Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation Event
2025-12-06 Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial Event
2025-12-03 Piper Sandler 37th Annual Healthcare Conference Conference
2025-11-18 Jefferies Global Healthcare Conference in London Conference
2025-11-13 Stifel 2025 Healthcare Conference Conference

Source: https://www.nurixtx.com/resource-library/

Key facts CIK 1549595 CUSIP 67080M103 13F (30d) 202 filings 193 filers Visit website Investor relations